Abstract
Background Hepatitis C virus (HCV) elimination requires treatment access expansion, especially for underserved populations. Telehealth has the potential to improve HCV treatment access, although data are limited on its incorporation into standard clinical practice.
Methods We conducted a cross-sectional, e-mail survey of 598 US HCV treatment providers who had valid email addresses and 1) were located in urban areas and had written ≥20 prescriptions for HCV treatment to US Medicare beneficiaries in 2019-20 or 2) were located in non-urban areas and wrote any HCV prescriptions in 2019-20. Through email, we notified providers of a self-administered electronic 28-item survey of clinical strategies and attitudes about telemedicine for HCV.
Results We received 86 responses (14% response rate), of which 75 used telemedicine for HCV in 2022. Of those 75, 24% were gastroenterologists/hepatologists, 23% general medicine, 17% infectious diseases, and 32% non-physicians. Most (82%) referred patients to commercial laboratories, and 85% had medications delivered directly to patients. Overwhelmingly, respondents (92%) felt that telehealth increases healthcare access, and 76% reported that it promotes or is neutral for treatment completion. Factors believed to be “extremely” or “very” important for telehealth use included patient access to technology (86%); patients’ internet access (74%); laboratory access (76%); reimbursement for video visits (74%) and audio-only visits (66%). Non-physician licensing and liability statutes were rated “extremely” or “very” important by 43% and 44%, respectively.
Conclusions Providers felt that telehealth increases HCV treatment access. Major limitations were technological requirements, reimbursement, and access to ancillary services. These findings support the importance of digital equity and literacy to achieve HCV elimination goals.
Competing Interest Statement
Dr Kapadia reports grants to his institution from Gilead Sciences Inc unrelated to the current study. Dr. Patel is part of the Speakers Bureau for Gilead Sciences. Dr. Talal reports grants to his institution from Gilead Sciences, Merck, and Abbott Laboratories. He has also served on advisory committees and as an advisor to Gilead Sciences, Novo Nordisk, and AbbVie. All other authors report no conflicts of interest.
Funding Statement
This work was supported in part by R01 DK123205 (to MS, MTW, EW, AHT), K01 DA048172 (to SNK), a Patient-Centered Outcomes Research Institute (PCORI) Award (IHS-1507-31640) (to AHT) and the Troup Fund of the Kaleida Health Foundation (to AHT). The opinions expressed in this work are those of the authors, and do not necessarily reflect the views of the funding agencies or the US Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of the Biomedical Research Alliance of New York (BRANY) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclosures: Dr Kapadia reports grants to his institution from Gilead Sciences Inc unrelated to the current study. Dr. Patel is part of the Speakers Bureau for Gilead Sciences. Dr. Talal reports grants to his institution from Gilead Sciences, Merck, and Abbott Laboratories. He has also served on advisory committees and as an advisor to Gilead Sciences, Novo Nordisk, and AbbVie. All other authors report no conflicts of interest.
Funding: This work was supported in part by R01 DK123205 (to MS, MTW, EW, AHT), K01 DA048172 (to SNK), a Patient-Centered Outcomes Research Institute (PCORI) Award (IHS-1507-31640) (to AHT) and the Troup Fund of the Kaleida Health Foundation (to AHT). The statements in this work solely the responsibility of the authors, and do not necessarily represent the views of PCORI, its Board of Governors or Methodology Committee, or the US Government.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
